rcv31n3.vp

Revista Uruguaya de Cardiología Actualización en medicamentos antidiabéticos y riesgo cardiovascular
Volumen 31 | nº 3 | Diciembre 2016 María del Pilar Serra Sansone




164. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, 174. ThrainsdottirI,MalmbergK,OlssonA,Gutniak
Drucker DJ, Husain M. Cardioprotective and vaso- M, Rydén L. Initial experience with GLP-1 treatment
dilatory actions of glucagon-like peptide 1 receptor are on metabolic control and myocardial function in pa-
mediated through both glucagon-like peptide 1 recep- tients with type 2 diabetes mellitus and heart failure.
tor-dependent and –independent pathways. Circula- Diab Vasc Dis Res 2004; 1(1):40-3.
tion 2008; 117(18):2340-50.
175. Nikolaidis LA, Mankad S, Sokos GG, Miske G,
165. DeFronzo RA, Ratner RE, Han J, Kim DD, Fine- Shah A, Elahi D, et al. Effects of glucagon-like pepti-
manMS, BaronAD. Effects of exenatide (exendin-4) de-1 in patients with acute myocardial infarction and
on glycemic control and weight over 30 weeks in met- left ventricular dysfunction after successful reperfu-
formin-treated patients with type 2 diabetes. Diabetes sion. Circulation 2004; 109(8):962-5.
Care 2005; 28(5):1092-100.
176. Read PA, Khan FZ, Dutka DP. Cardioprotection
166. Buse JB, Rosenstock J, Sesti G, Schmidt WE, against ischaemia induced by dobutamine stress using
Montanya E, Brett JH, et al; LEAD-6 Study glucagon-like peptide-1 in patients with coronary ar-
Group. Liraglutideonceadayversusexenatide twicea tery disease. Heart 2012; 98(5):408-13.
day for type 2 diabetes: a 26-week randomised, para- 177. Read PA, Hoole SP, White PA, Khan FZ, O’Sulli-
llel-group, multinational, open-label trial (LEAD-6). van M, West NE, et al.Apilotstudytoassesswhether
Lancet 2009; 374(9683):39-47. glucagon-like peptide-1 protects the heart from ische-
mic dysfunction and attenuates stunning after coro-
167. ChiltonR,Wyatt J, NandishS,OliverosR,Lujan
nary balloon occlusion in humans. Circ Cardiovasc
M. Cardiovascular comorbidities of type 2 diabetes me-
Interv 2011; 4(3):266-72.
llitus: defining the potential of glucagonlike pepti-
de-1-based therapies. Am J Med 2011; 124(1 178. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE,
Suppl):S35-53. Kim WY, Mathiasen AB, et al. Exenatide reduces re-
perfusion injury in patients with ST-segment elevation
168. Kavianipour M, Ehlers MR, Malmberg K, Ron-
myocardial infarction. Eur Heart J 2012;
quist G, Ryden L, Wikström G, et al. Glucagon-like
33(12):1491-9.
peptide-1 (7-36) amide prevents the accumulation of
pyruvate and lactate in the ischemic and non-ischemic 179. Davies M, Bode BW, Kushner R, Lewin AJ,
porcine myocardium. Peptides 2003; 24(4):569-78 Skjoth TV, Jensen CB, et al. Liraglutide 3.0 mg for
weight management in obese/overweight adults with
169. Poornima I, Brown SB, Bhashyam S, Parikh P, Type 2 diabetes: results from the SCALETM diabetes
Bolukoglu H, Shannon RP. Chronic glucagon-like 56-week randomized, double-blind, placebo-controlled
peptide-1 infusion sustains left ventricular systolic trial. Diabetes 2014; 63(Suppl 1):A26.
function and prolongs survival in the spontaneously
180. Okerson T, Yan P, Stonehouse A, Brodows R.
hypertensive, heart failure-prone rat. Circ Heart Fail
Effects of exenatide on systolic blood pressure in sub-
2008; 1(3):153-60.
jects with type 2 diabetes. Am J Hypertens 2010;
170. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, 23(3):334-9.
Huerbin R, Zourelias L, et al. Recombinant gluca-
181. Drucker DJ, Buse JB, Taylor K, Kendall DM,
gon-like peptide-1 increasesmyocardial glucose uptake
Trautmann M, Zhuang D, et al; DURATION-1
and improves left ventricular performance in conscious
Study Group. Exenatide once weekly versus twice
dogs with pacing-induced dilated cardiomyopathy. Cir-
daily for the treatment of type 2 diabetes: a randomi-
culation 2004;110(8):955-61.
sed, open-label, non-inferiority study. Lancet 2008;
171. Nathanson D, Ullman B, Löfström U, Hedman A, 372(9645):1240-50.
Frick M, Sjöholm A, et al. Effects of intravenous
182. Fonseca VA, Devries JH, Henry RR, Donsmark
exenatide in type 2 diabetic patients with congestive
M, Thomsen HF, Plutzky J. Reductions in systolic
heart failure: a double-blind, randomised controlled cli-
blood pressure with liraglutide in patients with type 2
nical trial of efficacy and safety. Diabetologia 2012;
diabetes: insights from a patient-level pooled analysis
55(4):926-35.
of six randomized clinical trials. J Diabetes Complica-
172. Timmers L, Henriques JP, de Kleijn DP, Devries tions 2014; 28(3):399-405.
JH, Kemperman H, Steendijk P, et al. Exenatide 183. Schwartz EA, Koska J, Mullin MP, Syoufi I,
reduces infarct size and improves cardiac function in a Schwenke DC, Reaven PD. Exenatide suppresses
porcine model of ischemia and reperfusion injury. J Am postprandial elevations in lipids and lipoproteins in in-
Coll Cardiol 2009; 53(6):501-10. dividuals with impaired glucose tolerance and recent
onset type 2 diabetes mellitus. Atherosclerosis 2010;
173. Sokos GG, Nikolaidis LA, Mankad S, Elahi D,
212(1):217-22.
Shannon RP. Glucagon-like peptide-1 infusion im-
proves left ventricular ejection fraction and functional 184. Meier JJ, Gethmann A, Götze O, Gallwitz B,
status in patients with chronic heart failure. J Card Holst JJ, Schmidt WE, et al. Glucagon-like peptide
Fail 2006; 12(9):694-9. 1 abolishes the postprandial rise in triglyceride concen-
545

Actualización en medicamentos antidiabéticos y riesgo cardiovascular Revista Uruguaya de Cardiología
María del Pilar Serra Sansone Volumen 31 | nº 3 | Diciembre 2016




trations and lowers levels of non-esterified fatty acids 194. Henry RR, Gumbiner B, Ditzler T, Wallace P,
in humans. Diabetologia 2006; 49(3):452-8. Lyon R, Glauber HS. Intensive conventional insulin
therapy for type II diabetes. Metabolic effects during a
185. KendallDM, BholeD,GuanX,Nielsen L, Traut-
6-mooutpatienttrial.DiabetesCare1993;16(1):21-31.
mann M, Wintle M, et al. Exenatide treatment for 82
weeks reduced C-reactive protein, HbA1c, and body 195. Holden SE, Currie CJ. Mortalityriskwithsulphony-
weight in patients with type 2 diabetes mellitus. Diabe- lureas compared to metformin. Diabetes Obes Metab
tologia2006;49(Suppl 1):475. 2014; 16(10):885-90.
186. Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi 196. Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P,
T, Krarup T, Schmitz O, et al. Beneficial effects of Ramachandran A, Hâncu N, et al; GRACE and
once-daily liraglutide, a human glucagon-like peptide-1 ORIGIN Investigators. Effect of insulin glargine
analogue, on cardiovascular risk biomarkers in pa- and n-3FA on carotid intima-media thickness in people
tients with Type 2 diabetes. Diabet Med 2008; with dysglycemia at high risk for cardiovascular
25(9):1129-31. events: the glucose reduction and atherosclerosis conti-
187. LiuH,HuY,Simpson RW,DearAE. Glucagon-like nuing evaluation study (ORIGIN-GRACE). Diabetes
peptide-1 attenuates tumour necrosis factor-alpha-me- Care 2013; 36(9):2466-74.
diated induction of plasminogen [corrected] activator 197. Gamble JM,Simpson SH,EurichDT, Majumdar
inhibitor-1 expression. J Endocrinol 2008; SR, Johnson JA. Insulin use and increased risk of
196(1):57-65. mortality in type 2 diabetes: a cohort study. Diabetes
188. Liu H, Dear AE, Knudsen LB, Simpson RW. A Obes Metab 2010; 12(1):47-53.
long-acting glucagon-like peptide-1 analogue attenua-
198. Currie CJ, Poole CD, Evans M, Peters JR, Mor-
tes induction of plasminogen activator inhibitor type-1
gan CL. Mortality and other important diabetes-rela-
and vascular adhesion molecules. J Endocrinol 2009;
ted outcomes with insulin vs other antihyperglycemic
201(1):59-66.
therapies in type 2 diabetes. J Clin Endocrinol Metab
189. Kim Chung le T, Hosaka T, Yoshida M, Harada 2013; 98(2):668-77.
N, Sakaue H, Sakai T, et al. Exendin-4, a GLP-1 re-
199. Currie CJ, Peters JR, Tynan A, Evans M, Heine
ceptor agonist, directly induces adiponectin expression
RJ,Bracco OL,etal. Survival as a function of
through protein kinase A pathway and prevents in-
HbA(1c) in people with type 2 diabetes: a retrospective
flammatory adipokine expression. Biochem Biophys
cohort study. Lancet 2010; 375(9713):481-9.
Res Commun 2009; 390(3):613-8.
200. Colayco DC, Niu F, McCombs JS, Cheetham TC.
190. Best JH, Hoogwerf BJ, Herman WH, Pelletier
A1C and cardiovascular outcomes in type 2 diabetes: a
EM,Smith DB,WentenM,etal. Risk of cardiovas-
nested case-control study. Diabetes Care 2011;
cular disease events in patients with type 2 diabetes
34(1):77-83.
prescribed the glucagon-like peptide 1 (GLP-1) recep-
tor agonist exenatide twice daily or other glucose-lowe- 201. Eurich DT, Simpson S, Senthilselvan A, Asche
ring therapies: a retrospective analysis of the LifeLink CV, Sandhu-Minhas JK, McAlister FA. Compara-
database. Diabetes Care 2011; 34(1):90-5. tive safety and effectiveness of sitagliptin in patients
191. Pfeffer MA, Claggett B, Diaz R, Dickstein K, with type 2 diabetes: retrospective population based
Gerstein HC, Køber LV, et al; ELIXA Investiga- cohort study. BMJ 2013; 346:f2267.
tors. Lixisenatide in patients with Type 2 diabetes and
202. Lachin JM, Orchard TJ, Nathan DM; DCCT/
acute coronary syndrome. N Engl J Med 2015;
EDIC Research Group. Update on cardiovascular
373(23):2247-57.
outcomes at 30 years of the diabetes control and com-
192. Marso SP, Daniels GH, Brown-Frandsen K, Kris- plications trial/epidemiology of diabetes interventions
tensen P, Mann JF, Nauck MA, et al; LEADER and complications study. Diabetes Care 2014;
Steering Committee; LEADER Trial Investiga- 37(1):39-43.
tors. Liraglutide and Cardiovascular Outcomes in
203. Writing Group for the DCCT/EDIC Research
Type2Diabetes.NEnglJMed2016;375(4):311-22.
Group; Orchard TJ, Nathan DM, Zinman B,
193. Kim JY, Yang S, Lee JI, Chang MJ. Cardiovascular Cleary P, Brillon D, Backlund JY, et al. Associa-
effect of incretin-based therapy in patients with Type 2 tion between 7 years of intensive treatment of type 1
diabetes mellitus: systematic review and meta-analy- diabetes and long-term mortality. JAMA 2015;
sis. PLoS One 2016; 11(4):e0153502. 313(1):45-53.






546

Revista Uruguaya de Cardiología
Volumen 31 | nº 3 | Diciembre 2016





Aclaración sobre Temas Libres Premiados del

31º Congreso Uruguayo de Cardiología 2015




En el Suplemento 1, volumen 30, de Diciembre 2015 de nuestra Revista se publicaron los sie-
te Temas Libres premiados del 31º Congreso Uruguayo de Cardiología.
Deseamos informar que el Tema Libre identificado con el número 59 y titulado: "En niños
y adolescentesuna mala calidad alimenticia asocia menor función endotelial y mayor nivel de
rigidez aórtica con independencia del peso corporal" presentado por los Dres. y Bachilleres
Curcio, Arana, García Espinosa, Mattos, Estavillo, Chiesa, Giachietto, Zocalo y Bia, ha perdi-
do su condición de tal debido a aspectos reglamentarios.
El Comité Cientifico del Congreso designó en consecuencia como mejor Tema Libre de
Investigador Joven al No. 54: “Valor pronóstico del ecocardiograma estrés con fármacos”
presentado por los Dres. Mussacco, Moreira, Perez Arrarte, Ricca y Vázquez.



Consejo Editorial
Revista Uruguaya de Cardiología
















































547